| Joseph Scott Langford, MD | |
|
1320 Maplewood Ave, Ronceverte, WV 24970-8016 | |
| (304) 793-2220 | |
| (304) 793-2277 |
| Full Name | Joseph Scott Langford |
|---|---|
| Gender | Male |
| Speciality | Emergency Medicine |
| Experience | 27 Years |
| Location | 1320 Maplewood Ave, Ronceverte, West Virginia |
| Accepts Medicare Assignments | May be. He may accept the Medicare-approved amount; you may be billed for more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1063476992 | NPI | - | NPPES |
| 89127EY | Medicaid | NC | |
| 930107011 | Other | NC | RAILROAD |
| Q0086P | Medicaid | SC | |
| 1354M | Other | NC | BCBS |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207P00000X | Emergency Medicine | 200000869 (North Carolina) | Secondary |
| 207P00000X | Emergency Medicine | 29861 (West Virginia) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| University Of Tn Medical Center | Knoxville, TN | Hospital |
| Blount Memorial Hospital | Maryville, TN | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Southeastern Emergency Physicians Llc | 2466364997 | 491 |
News Archive
Gastrointestinal (GI) chronic perforations require closure and control of extraluminal collections and sepsis. Covered self-expandable metal stents or plastic stents are an effective method in more than 80% of cases, but have many drawbacks.
A growing body of evidence suggests that virtual reality (VR) technology can be an effective part of treatment for phobias, posttraumatic stress disorder, and other mental health conditions, according to a research review in the May/June issue of the Harvard Review of Psychiatry. The journal is published by Wolters Kluwer.
When aggressive, malignant tumors appear in more than one location in the brain, patient survival tends to be significantly shorter than when the disease starts as a single tumor, even though patients in both groups undergo virtually identical treatments, according to research at Cedars-Sinai Medical Center's Maxine Dunitz Neurosurgical Research Institute.
Perrigo Company today announced that it has received final approval from the U.S. Food and Drug Administration for its abbreviated new drug application for Ketoconazole Foam, 2%, the generic version of Extina Ketoconazole Foam, 2%.
Covidien, a leading global provider of healthcare products, and Nuvo Research Inc., a Canadian drug development company, today announced that the U.S. Food and Drug Administration (FDA) has approved the New Drug Application for Pennsaid(R) Topical Solution (diclofenac sodium topical solution) 1.5% w/w.
› Verified 2 days ago
| Entity Name | Emergency Medicine Physicians Of Carteret County Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1538108535 PECOS PAC ID: 0042122582 Enrollment ID: O20031103000502 |
News Archive
Gastrointestinal (GI) chronic perforations require closure and control of extraluminal collections and sepsis. Covered self-expandable metal stents or plastic stents are an effective method in more than 80% of cases, but have many drawbacks.
A growing body of evidence suggests that virtual reality (VR) technology can be an effective part of treatment for phobias, posttraumatic stress disorder, and other mental health conditions, according to a research review in the May/June issue of the Harvard Review of Psychiatry. The journal is published by Wolters Kluwer.
When aggressive, malignant tumors appear in more than one location in the brain, patient survival tends to be significantly shorter than when the disease starts as a single tumor, even though patients in both groups undergo virtually identical treatments, according to research at Cedars-Sinai Medical Center's Maxine Dunitz Neurosurgical Research Institute.
Perrigo Company today announced that it has received final approval from the U.S. Food and Drug Administration for its abbreviated new drug application for Ketoconazole Foam, 2%, the generic version of Extina Ketoconazole Foam, 2%.
Covidien, a leading global provider of healthcare products, and Nuvo Research Inc., a Canadian drug development company, today announced that the U.S. Food and Drug Administration (FDA) has approved the New Drug Application for Pennsaid(R) Topical Solution (diclofenac sodium topical solution) 1.5% w/w.
› Verified 2 days ago
| Entity Name | Transylvania Community Hospital Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1174549208 PECOS PAC ID: 4880592427 Enrollment ID: O20031222000135 |
News Archive
Gastrointestinal (GI) chronic perforations require closure and control of extraluminal collections and sepsis. Covered self-expandable metal stents or plastic stents are an effective method in more than 80% of cases, but have many drawbacks.
A growing body of evidence suggests that virtual reality (VR) technology can be an effective part of treatment for phobias, posttraumatic stress disorder, and other mental health conditions, according to a research review in the May/June issue of the Harvard Review of Psychiatry. The journal is published by Wolters Kluwer.
When aggressive, malignant tumors appear in more than one location in the brain, patient survival tends to be significantly shorter than when the disease starts as a single tumor, even though patients in both groups undergo virtually identical treatments, according to research at Cedars-Sinai Medical Center's Maxine Dunitz Neurosurgical Research Institute.
Perrigo Company today announced that it has received final approval from the U.S. Food and Drug Administration for its abbreviated new drug application for Ketoconazole Foam, 2%, the generic version of Extina Ketoconazole Foam, 2%.
Covidien, a leading global provider of healthcare products, and Nuvo Research Inc., a Canadian drug development company, today announced that the U.S. Food and Drug Administration (FDA) has approved the New Drug Application for Pennsaid(R) Topical Solution (diclofenac sodium topical solution) 1.5% w/w.
› Verified 2 days ago
| Entity Name | Emergency Medicine Physicians Of Craven County Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1164462586 PECOS PAC ID: 0042106478 Enrollment ID: O20040224000355 |
News Archive
Gastrointestinal (GI) chronic perforations require closure and control of extraluminal collections and sepsis. Covered self-expandable metal stents or plastic stents are an effective method in more than 80% of cases, but have many drawbacks.
A growing body of evidence suggests that virtual reality (VR) technology can be an effective part of treatment for phobias, posttraumatic stress disorder, and other mental health conditions, according to a research review in the May/June issue of the Harvard Review of Psychiatry. The journal is published by Wolters Kluwer.
When aggressive, malignant tumors appear in more than one location in the brain, patient survival tends to be significantly shorter than when the disease starts as a single tumor, even though patients in both groups undergo virtually identical treatments, according to research at Cedars-Sinai Medical Center's Maxine Dunitz Neurosurgical Research Institute.
Perrigo Company today announced that it has received final approval from the U.S. Food and Drug Administration for its abbreviated new drug application for Ketoconazole Foam, 2%, the generic version of Extina Ketoconazole Foam, 2%.
Covidien, a leading global provider of healthcare products, and Nuvo Research Inc., a Canadian drug development company, today announced that the U.S. Food and Drug Administration (FDA) has approved the New Drug Application for Pennsaid(R) Topical Solution (diclofenac sodium topical solution) 1.5% w/w.
› Verified 2 days ago
| Entity Name | Carolina Mountain Emergency Medicine Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1457317620 PECOS PAC ID: 0345223798 Enrollment ID: O20040608001059 |
News Archive
Gastrointestinal (GI) chronic perforations require closure and control of extraluminal collections and sepsis. Covered self-expandable metal stents or plastic stents are an effective method in more than 80% of cases, but have many drawbacks.
A growing body of evidence suggests that virtual reality (VR) technology can be an effective part of treatment for phobias, posttraumatic stress disorder, and other mental health conditions, according to a research review in the May/June issue of the Harvard Review of Psychiatry. The journal is published by Wolters Kluwer.
When aggressive, malignant tumors appear in more than one location in the brain, patient survival tends to be significantly shorter than when the disease starts as a single tumor, even though patients in both groups undergo virtually identical treatments, according to research at Cedars-Sinai Medical Center's Maxine Dunitz Neurosurgical Research Institute.
Perrigo Company today announced that it has received final approval from the U.S. Food and Drug Administration for its abbreviated new drug application for Ketoconazole Foam, 2%, the generic version of Extina Ketoconazole Foam, 2%.
Covidien, a leading global provider of healthcare products, and Nuvo Research Inc., a Canadian drug development company, today announced that the U.S. Food and Drug Administration (FDA) has approved the New Drug Application for Pennsaid(R) Topical Solution (diclofenac sodium topical solution) 1.5% w/w.
› Verified 2 days ago
| Entity Name | Southeastern Emergency Physicians Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1356379382 PECOS PAC ID: 2466364997 Enrollment ID: O20050415000720 |
News Archive
Gastrointestinal (GI) chronic perforations require closure and control of extraluminal collections and sepsis. Covered self-expandable metal stents or plastic stents are an effective method in more than 80% of cases, but have many drawbacks.
A growing body of evidence suggests that virtual reality (VR) technology can be an effective part of treatment for phobias, posttraumatic stress disorder, and other mental health conditions, according to a research review in the May/June issue of the Harvard Review of Psychiatry. The journal is published by Wolters Kluwer.
When aggressive, malignant tumors appear in more than one location in the brain, patient survival tends to be significantly shorter than when the disease starts as a single tumor, even though patients in both groups undergo virtually identical treatments, according to research at Cedars-Sinai Medical Center's Maxine Dunitz Neurosurgical Research Institute.
Perrigo Company today announced that it has received final approval from the U.S. Food and Drug Administration for its abbreviated new drug application for Ketoconazole Foam, 2%, the generic version of Extina Ketoconazole Foam, 2%.
Covidien, a leading global provider of healthcare products, and Nuvo Research Inc., a Canadian drug development company, today announced that the U.S. Food and Drug Administration (FDA) has approved the New Drug Application for Pennsaid(R) Topical Solution (diclofenac sodium topical solution) 1.5% w/w.
› Verified 2 days ago
| Entity Name | Blue Ridge Regional Hospital, Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1679570840 PECOS PAC ID: 0648181966 Enrollment ID: O20060410000335 |
News Archive
Gastrointestinal (GI) chronic perforations require closure and control of extraluminal collections and sepsis. Covered self-expandable metal stents or plastic stents are an effective method in more than 80% of cases, but have many drawbacks.
A growing body of evidence suggests that virtual reality (VR) technology can be an effective part of treatment for phobias, posttraumatic stress disorder, and other mental health conditions, according to a research review in the May/June issue of the Harvard Review of Psychiatry. The journal is published by Wolters Kluwer.
When aggressive, malignant tumors appear in more than one location in the brain, patient survival tends to be significantly shorter than when the disease starts as a single tumor, even though patients in both groups undergo virtually identical treatments, according to research at Cedars-Sinai Medical Center's Maxine Dunitz Neurosurgical Research Institute.
Perrigo Company today announced that it has received final approval from the U.S. Food and Drug Administration for its abbreviated new drug application for Ketoconazole Foam, 2%, the generic version of Extina Ketoconazole Foam, 2%.
Covidien, a leading global provider of healthcare products, and Nuvo Research Inc., a Canadian drug development company, today announced that the U.S. Food and Drug Administration (FDA) has approved the New Drug Application for Pennsaid(R) Topical Solution (diclofenac sodium topical solution) 1.5% w/w.
› Verified 2 days ago
| Entity Name | Angel Medical Center Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1497753651 PECOS PAC ID: 9638253297 Enrollment ID: O20090312000353 |
News Archive
Gastrointestinal (GI) chronic perforations require closure and control of extraluminal collections and sepsis. Covered self-expandable metal stents or plastic stents are an effective method in more than 80% of cases, but have many drawbacks.
A growing body of evidence suggests that virtual reality (VR) technology can be an effective part of treatment for phobias, posttraumatic stress disorder, and other mental health conditions, according to a research review in the May/June issue of the Harvard Review of Psychiatry. The journal is published by Wolters Kluwer.
When aggressive, malignant tumors appear in more than one location in the brain, patient survival tends to be significantly shorter than when the disease starts as a single tumor, even though patients in both groups undergo virtually identical treatments, according to research at Cedars-Sinai Medical Center's Maxine Dunitz Neurosurgical Research Institute.
Perrigo Company today announced that it has received final approval from the U.S. Food and Drug Administration for its abbreviated new drug application for Ketoconazole Foam, 2%, the generic version of Extina Ketoconazole Foam, 2%.
Covidien, a leading global provider of healthcare products, and Nuvo Research Inc., a Canadian drug development company, today announced that the U.S. Food and Drug Administration (FDA) has approved the New Drug Application for Pennsaid(R) Topical Solution (diclofenac sodium topical solution) 1.5% w/w.
› Verified 2 days ago
| Entity Name | Emergency Coverage Corp |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1427005008 PECOS PAC ID: 3072412592 Enrollment ID: O20100202000365 |
News Archive
Gastrointestinal (GI) chronic perforations require closure and control of extraluminal collections and sepsis. Covered self-expandable metal stents or plastic stents are an effective method in more than 80% of cases, but have many drawbacks.
A growing body of evidence suggests that virtual reality (VR) technology can be an effective part of treatment for phobias, posttraumatic stress disorder, and other mental health conditions, according to a research review in the May/June issue of the Harvard Review of Psychiatry. The journal is published by Wolters Kluwer.
When aggressive, malignant tumors appear in more than one location in the brain, patient survival tends to be significantly shorter than when the disease starts as a single tumor, even though patients in both groups undergo virtually identical treatments, according to research at Cedars-Sinai Medical Center's Maxine Dunitz Neurosurgical Research Institute.
Perrigo Company today announced that it has received final approval from the U.S. Food and Drug Administration for its abbreviated new drug application for Ketoconazole Foam, 2%, the generic version of Extina Ketoconazole Foam, 2%.
Covidien, a leading global provider of healthcare products, and Nuvo Research Inc., a Canadian drug development company, today announced that the U.S. Food and Drug Administration (FDA) has approved the New Drug Application for Pennsaid(R) Topical Solution (diclofenac sodium topical solution) 1.5% w/w.
› Verified 2 days ago
| Entity Name | Highlands-cashiers Physician Services Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1851685051 PECOS PAC ID: 6103096433 Enrollment ID: O20110824000544 |
News Archive
Gastrointestinal (GI) chronic perforations require closure and control of extraluminal collections and sepsis. Covered self-expandable metal stents or plastic stents are an effective method in more than 80% of cases, but have many drawbacks.
A growing body of evidence suggests that virtual reality (VR) technology can be an effective part of treatment for phobias, posttraumatic stress disorder, and other mental health conditions, according to a research review in the May/June issue of the Harvard Review of Psychiatry. The journal is published by Wolters Kluwer.
When aggressive, malignant tumors appear in more than one location in the brain, patient survival tends to be significantly shorter than when the disease starts as a single tumor, even though patients in both groups undergo virtually identical treatments, according to research at Cedars-Sinai Medical Center's Maxine Dunitz Neurosurgical Research Institute.
Perrigo Company today announced that it has received final approval from the U.S. Food and Drug Administration for its abbreviated new drug application for Ketoconazole Foam, 2%, the generic version of Extina Ketoconazole Foam, 2%.
Covidien, a leading global provider of healthcare products, and Nuvo Research Inc., a Canadian drug development company, today announced that the U.S. Food and Drug Administration (FDA) has approved the New Drug Application for Pennsaid(R) Topical Solution (diclofenac sodium topical solution) 1.5% w/w.
› Verified 2 days ago
| Entity Name | Mission Health Community Multispecialty Providers Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1457719130 PECOS PAC ID: 9537468574 Enrollment ID: O20160426001883 |
News Archive
Gastrointestinal (GI) chronic perforations require closure and control of extraluminal collections and sepsis. Covered self-expandable metal stents or plastic stents are an effective method in more than 80% of cases, but have many drawbacks.
A growing body of evidence suggests that virtual reality (VR) technology can be an effective part of treatment for phobias, posttraumatic stress disorder, and other mental health conditions, according to a research review in the May/June issue of the Harvard Review of Psychiatry. The journal is published by Wolters Kluwer.
When aggressive, malignant tumors appear in more than one location in the brain, patient survival tends to be significantly shorter than when the disease starts as a single tumor, even though patients in both groups undergo virtually identical treatments, according to research at Cedars-Sinai Medical Center's Maxine Dunitz Neurosurgical Research Institute.
Perrigo Company today announced that it has received final approval from the U.S. Food and Drug Administration for its abbreviated new drug application for Ketoconazole Foam, 2%, the generic version of Extina Ketoconazole Foam, 2%.
Covidien, a leading global provider of healthcare products, and Nuvo Research Inc., a Canadian drug development company, today announced that the U.S. Food and Drug Administration (FDA) has approved the New Drug Application for Pennsaid(R) Topical Solution (diclofenac sodium topical solution) 1.5% w/w.
› Verified 2 days ago
| Entity Name | Murphy Emergency Physicians, Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1053808378 PECOS PAC ID: 8628328424 Enrollment ID: O20180828003630 |
News Archive
Gastrointestinal (GI) chronic perforations require closure and control of extraluminal collections and sepsis. Covered self-expandable metal stents or plastic stents are an effective method in more than 80% of cases, but have many drawbacks.
A growing body of evidence suggests that virtual reality (VR) technology can be an effective part of treatment for phobias, posttraumatic stress disorder, and other mental health conditions, according to a research review in the May/June issue of the Harvard Review of Psychiatry. The journal is published by Wolters Kluwer.
When aggressive, malignant tumors appear in more than one location in the brain, patient survival tends to be significantly shorter than when the disease starts as a single tumor, even though patients in both groups undergo virtually identical treatments, according to research at Cedars-Sinai Medical Center's Maxine Dunitz Neurosurgical Research Institute.
Perrigo Company today announced that it has received final approval from the U.S. Food and Drug Administration for its abbreviated new drug application for Ketoconazole Foam, 2%, the generic version of Extina Ketoconazole Foam, 2%.
Covidien, a leading global provider of healthcare products, and Nuvo Research Inc., a Canadian drug development company, today announced that the U.S. Food and Drug Administration (FDA) has approved the New Drug Application for Pennsaid(R) Topical Solution (diclofenac sodium topical solution) 1.5% w/w.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Joseph Scott Langford, MD 1320 Maplewood Ave, Ronceverte, WV 24970-8016 Ph: (304) 793-2220 | Joseph Scott Langford, MD 1320 Maplewood Ave, Ronceverte, WV 24970-8016 Ph: (304) 793-2220 |
News Archive
Gastrointestinal (GI) chronic perforations require closure and control of extraluminal collections and sepsis. Covered self-expandable metal stents or plastic stents are an effective method in more than 80% of cases, but have many drawbacks.
A growing body of evidence suggests that virtual reality (VR) technology can be an effective part of treatment for phobias, posttraumatic stress disorder, and other mental health conditions, according to a research review in the May/June issue of the Harvard Review of Psychiatry. The journal is published by Wolters Kluwer.
When aggressive, malignant tumors appear in more than one location in the brain, patient survival tends to be significantly shorter than when the disease starts as a single tumor, even though patients in both groups undergo virtually identical treatments, according to research at Cedars-Sinai Medical Center's Maxine Dunitz Neurosurgical Research Institute.
Perrigo Company today announced that it has received final approval from the U.S. Food and Drug Administration for its abbreviated new drug application for Ketoconazole Foam, 2%, the generic version of Extina Ketoconazole Foam, 2%.
Covidien, a leading global provider of healthcare products, and Nuvo Research Inc., a Canadian drug development company, today announced that the U.S. Food and Drug Administration (FDA) has approved the New Drug Application for Pennsaid(R) Topical Solution (diclofenac sodium topical solution) 1.5% w/w.
› Verified 2 days ago
Mr. Tom A Sayvetz, MD Emergency Medicine Medicare: Not Enrolled in Medicare Practice Location: 202 Maplewood Ave, Greenbrier Valley Medical Center, Ronceverte, WV 24970 Phone: 304-647-4411 Fax: 304-647-6064 | |
Suzan R Myles, DO Emergency Medicine Medicare: Medicare Enrolled Practice Location: 202 Maplewood Ave, Ronceverte, WV 24970 Phone: 304-647-4411 | |
Dr. Alexis Marco Rodriguez, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 1320 Maplewood Ave, Ronceverte, WV 24970 Phone: 304-793-2220 Fax: 304-793-2277 |